US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

VanEck Biotech ETF

240.47

+6.432.75%

Post-market: 240.14-0.3266-0.14%19:30 EDT

Volume:10.88K

Turnover:2.60M

Market Cap:482.50M

PE:- -

High:240.47

Open:234.08

Low:234.08

Close:234.03

52wk High:246.55

52wk Low:171.63

Shares:2.01M

Float Shares:2.01M

Volume Ratio:0.89

T/O Rate:0.54%

Dividend:0.96

Dividend Rate:0.40%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Amgen’s Pediatric Psoriasis Study in Japan Wraps Up, Setting the Stage for Otezla Growth

Expanded Sanofi agreement particularly favorable for Regeneron, says TD Cowen

Walt Disney, Amgen Share Losses Lead Dow's 150-Point Fall

Regeneron says COURAGE trial confirms trevogrumab prevents muscle loss

Regeneron Pharmaceuticals, - 9-Month Median Duration of Response Observed at 800 Mg Ubamatamab Dose

THOMSON REUTERS

Regeneron Pharmaceuticals, - Ubamatamab Shows 73% Objective Response Rate and 11-Month Median Pfs in Lgsoc Patients

THOMSON REUTERS

Regeneron Pharmaceuticals, - Serious Teaes Grade 3+ in 21% of Lgsoc Patients; Traes in 74%; Neutropenia, Anemia, Elevated Liver Enzymes

THOMSON REUTERS

Regeneron Pharmaceuticals, - to Advance Ubamatamab into Confirmatory Phase 3 Trial for Lgsoc

THOMSON REUTERS

Ubamatamab (Muc16xcd3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (Lgsoc)

THOMSON REUTERS

Ubamatamab (MUC16xCD3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (LGSOC)

Regeneron Says Phase 2 Courage Trial Shows Trevogrumab Preserves Lean Mass During Semaglutide Weight Loss

Regeneron Pharmaceuticals, - Lower Doses of Trevogrumab Well Tolerated with 77% Experiencing at Least One Adverse Event

THOMSON REUTERS

Regeneron Pharmaceuticals, - Plans Phase 2 Trial of Trevogrumab with Glp-1 Therapies in Older Adults

THOMSON REUTERS

Phase 2 Courage Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During Glp-1 Receptor Agonist-Induced Weight Loss

THOMSON REUTERS

Regeneron Pharmaceuticals, - Trevogrumab Prevents 70% of Muscle Loss Associated with Semaglutide Treatment

THOMSON REUTERS

Gilead Sciences Announces Dividend of R$ 0.2394442440 Per Unit for Brgildbdr 000

Regeneron Exec Says Co Eligible to Receive $1 Bln in Potential Milestone Payment with the Start of the First Late-Stage Trial as Part of the Deal -Conf Call

THOMSON REUTERS

Regeneron Exec Says Co Expects to Start Pivotal Study for Regn20423 Either in Late 2027 or Early 2028

THOMSON REUTERS

Regeneron Pharma Price Target Announced at $850.00/Share by Argus Research

Vir Biotechnology Names Aziz Sawaf as CFO Effective Oct. 5, 2026

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/stock/BBH/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BBH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BBH\",,,,,undefined,":{"symbol":"BBH","market":"US","secType":"STK","nameCN":"VanEck Biotech ETF","latestPrice":240.4666,"timestamp":1791576000000,"preClose":234.0318,"halted":0,"volume":10884,"hourTrading":{"tag":"盘后","latestPrice":240.14,"preClose":240.4666,"latestTime":"19:30 EDT","volume":12,"amount":2883.9364,"timestamp":1791588606301,"change":-0.3266,"changeRate":-0.001358,"amplitude":0},"delay":0,"changeRate":0.027495408743598074,"floatShares":2006503,"shares":2006503,"eps":0,"marketStatus":"Market Closed","change":6.4348,"latestTime":"10-09 16:00:00 EDT","open":234.08,"high":240.4666,"low":234.08,"amount":2595064.39236,"amplitude":0.027289,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791792000000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":234.0318,"sharesOutstanding":1976503,"nav":240.40394,"aum":484775263.27,"dividendRate":0.00399,"bidAskSpread":0.001167,"postHourTrading":{"tag":"盘后","latestPrice":240.14,"preClose":240.4666,"latestTime":"19:30 EDT","volume":12,"amount":2883.9364,"timestamp":1791588606301,"change":-0.3266,"changeRate":-0.001358,"amplitude":0},"volumeRatio":0.8922189170173007,"impliedVol":0.1795,"impliedVolPercentile":0.2191},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BBH\",,,,,undefined,":{"symbol":"BBH","floatShares":2006503,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.8922189170173007,"shares":2006503,"dividePrice":0.9595,"high":240.4666,"amplitude":0.027289,"preClose":234.0318,"low":234.08,"week52Low":171.63,"pbRate":"--","week52High":246.55,"institutionHeld":0,"latestPrice":240.4666,"eps":0,"divideRate":0.00399,"volume":10884,"delay":0,"ttmEps":0,"open":234.08,"prevYearClose":189.2649,"prevWeekClose":237.4531,"prevMonthClose":244.575,"prevQuarterClose":244.575,"fiveDayClose":237.4531,"twentyDayClose":229.3922,"sixtyDayClose":206.2544},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BBH\",params:#limit:5,,,undefined,":[{"date":"2025-12-22","symbol":"BBH","amount":0.9565,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"VanEck Biotech ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-26","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-26"},{"date":"2024-12-23","symbol":"BBH","amount":1.2517,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-23","defaultRemindTime":1734964200000,"name":"VanEck Biotech ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-24","payableDate":"2024-12-23","currency":"USD","dateTimestamp":1734930000000,"payDate":"2024-12-24"},{"date":"2023-12-18","symbol":"BBH","amount":0.7127,"announcedDate":"2023-12-15","type":"dividend","market":"US","newRecordDate":"2023-12-19","defaultRemindTime":1702909800000,"name":"VanEck Biotech ETF","recordDate":"2023-12-22","payableDate":"2023-12-19","currency":"USD","dateTimestamp":1702875600000,"payDate":"2023-12-22"},{"market":"US","date":"2022-12-19","symbol":"BBH","amount":0.7488,"defaultRemindTime":1671460200000,"name":"VanEck Biotech ETF","recordDate":"2022-12-23","payableDate":"2022-12-20","currency":"USD","type":"dividend","dateTimestamp":1671426000000},{"market":"US","date":"2021-12-20","symbol":"BBH","amount":0.3972,"defaultRemindTime":1640010600000,"name":"VanEck Vectors Biotech ETF","recordDate":"2021-12-27","payableDate":"2021-12-21","currency":"USD","type":"dividend","dateTimestamp":1639976400000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BBH\",market:\"US\",,,undefined,":[{"executeDate":"2016-12-19","recordDate":"2016-12-21","paymentDate":"2016-12-23","value":0.327,"currency":"USD"},{"executeDate":"2018-12-20","recordDate":"2018-12-21","paymentDate":"2018-12-27","value":0.006,"currency":"USD"},{"executeDate":"2019-12-23","recordDate":"2019-12-24","paymentDate":"2019-12-30","value":0.4724,"currency":"USD"},{"executeDate":"2020-12-21","recordDate":"2020-12-22","paymentDate":"2020-12-28","value":0.6079,"currency":"USD"},{"executeDate":"2021-12-20","recordDate":"2021-12-21","paymentDate":"2021-12-27","value":0.3972,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BBH\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BBH\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2672476612","title":"Amgen’s Pediatric Psoriasis Study in Japan Wraps Up, Setting the Stage for Otezla Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2672476612","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672476612?lang=en_us&edition=fundamental","pubTime":"2026-10-02 00:30","pubTimestamp":1790872227,"startTime":"0","endTime":"0","summary":"Amgen Inc ($AMGN) announced an update on their ongoing clinical study. Amgen Inc. (AMGN) has completed a Phase 3 study called “A Phase 3, Multicent...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/amgens-pediatric-psoriasis-study-in-japan-wraps-up-setting-the-stage-for-otezla-growth?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/amgens-pediatric-psoriasis-study-in-japan-wraps-up-setting-the-stage-for-otezla-growth?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0122379950.USD","LU0889565916.HKD","IE0009355771.USD","LU0109394709.USD","BK4581","TBXU","LU1983299246.USD","PJP","LU1023059063.AUD","LU2468319806.SGD","BK4534","LU2242652126.USD","LU0320765992.SGD","LU0868494617.USD","LU0058720904.USD","IBBQ","LU0289739699.SGD","IE00B2B36J28.USD","PBE","IE00BJJMRZ35.SGD","IE0002141913.USD","LU1057294990.SGD","BK4139","BK4566","LU2242646821.SGD","SG9999001440.SGD","LU1571399168.USD","BK4585","BIB","IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","LU1061106388.HKD","IBB","LU2112291526.USD","BBH","IE00BJT1NW94.SGD","BK4599","BK4588","BK4533","LU2089984988.USD","AMGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672197766","title":"Expanded Sanofi agreement particularly favorable for Regeneron, says TD Cowen","url":"https://stock-news.laohu8.com/highlight/detail?id=2672197766","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672197766?lang=en_us&edition=fundamental","pubTime":"2026-10-02 00:20","pubTimestamp":1790871634,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Tyler Van Buren reiterated a Buy rating and $960 price target on Regeneron (REGN), saying the expanded agreement with Sanofi (SNY)...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/expanded-sanofi-agreement-particularly-favorable-for-regeneron-says-td-cowen-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/expanded-sanofi-agreement-particularly-favorable-for-regeneron-says-td-cowen-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2023250504.SGD","SNY","IBB","SNYNF","LU1917777945.USD","LU0889565916.HKD","BK4127","LU0882574055.USD","LU2362541273.HKD","LU0114720955.EUR","LU0109394709.USD","LU2468319806.SGD","LU2089984988.USD","BBH","BK4139","LU0823434583.USD","IE00BFXG1179.USD","REGN","TBXU","LU0823416689.USD","BK4585","LU0823434740.USD","LU2237438978.USD","LU2324357040.USD","LU2362540622.SGD","LU0053666078.USD","LU0058720904.USD","IBBQ","LU1974910355.USD","BK4588","LU0320765992.SGD","LU0289739699.SGD","LU2362541513.USD","COWN","BK4007","LU2106854487.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672076575","title":"Walt Disney, Amgen Share Losses Lead Dow's 150-Point Fall","url":"https://stock-news.laohu8.com/highlight/detail?id=2672076575","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672076575?lang=en_us&edition=fundamental","pubTime":"2026-10-02 00:09","pubTimestamp":1790870940,"startTime":"0","endTime":"0","summary":"DJ Walt Disney, Amgen Share Losses Lead Dow's 150-Point FallThis article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Walt Disney and Amgen are trading lower Thursday afternoon, sending the Dow Jones Industrial Average into negative territory.Shares of Walt Disney  and Amgen  are contributing to the index's intraday decline, as the Dow  was most recently trading 150 points lower .Walt Disney's shares are off $3.07  while those of Amgen are off $9.88 , combining for a roughly 77-point drag on the Dow.Also contributing significantly to the decline are Home Depot , American Express , and Apple .A $1 move in any of the index's 30 components equates to a 5.94-point swing.Data source: Dow Jones Market Data, FactSet. Data compiled October 1, 2026.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU0289739699.SGD","BK4599","IE0002141913.USD","LU0912757837.SGD","BK4598","LU1506573853.SGD","IE00B2B36J28.USD","LU0889565916.HKD","LU0011850046.USD","BBH","LU1035773651.USD","BK4588","VOX","LU2112291526.USD","BK4566","LU2242646821.SGD","LU0795875086.SGD","LU2357305700.SGD","LU1057294990.SGD","BK4550","TBXU","SG9999015952.SGD","LU1718418525.SGD","LU0208291251.USD","FCOM","LU0061475181.USD","LU0058720904.USD","LU1267930573.SGD","LU0726765562.USD","LU0314106906.USD","IE00BKVL7J92.USD","BK4524","LU2347655073.USD","LU2089984988.USD","SG9999015978.USD","IE00B19Z3581.USD","LU1548497426.USD","LU1069347547.HKD","BK4108","LU0640476718.USD","LU0122379950.USD","LU1732799900.SGD","LU1894683348.USD","LU0210533765.USD","LU0251142724.SGD","LU1280957306.USD","GB00BDT5M118.USD","BIB","04332","IBBQ","LU0070217475.USD","SG9999015986.USD","IE00BFTCPJ56.SGD","LU0320765489.SGD","LU2133065610.SGD","LU1023059063.AUD","BK4554","PJP","LU0048573561.USD","IE00B4R5TH58.HKD","IE00BJJMRZ35.SGD","LU1720051017.SGD","IE00B19Z3B42.SGD","IE00BJT1NW94.SGD","LU2468319806.SGD","BK4561","LU1894683264.USD","LU2347655156.SGD","IE0009355771.USD","LU0128525929.USD","LU0310800379.SGD","SG9999001440.SGD","LU0795875169.SGD","LU1732800096.USD","DISO","LU1571399168.USD","LU0029864427.USD","BK4551","AMGN","BK4507","IBB","LU0320765992.SGD","IE00B7SZLL34.SGD","LU0742534661.SGD","LU0070302665.USD","LU0109394709.USD","BK4534","LU1983299246.USD","LU1720051108.HKD","DIS","LU1061106388.HKD","LU0251131958.USD","BK4532","IE0002270589.USD","BK4581","LU0868494617.USD","PBE","WNDR","IE00BZ1G4Q59.USD","BK4139","SG9999015945.SGD","LU0786609619.USD","BK4533","LU0708994859.HKD","LU2242652126.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672765508","title":"Regeneron says COURAGE trial confirms trevogrumab prevents muscle loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2672765508","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672765508?lang=en_us&edition=fundamental","pubTime":"2026-10-01 23:35","pubTimestamp":1790868917,"startTime":"0","endTime":"0","summary":"Regeneron (REGN) Pharmaceuticals announced new results from the Phase 2 COURAGE trial evaluating trevogrumab for its potential to prevent lean mass...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/regeneron-says-courage-trial-confirms-trevogrumab-prevents-muscle-loss-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/regeneron-says-courage-trial-confirms-trevogrumab-prevents-muscle-loss-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0109394709.USD","BBH","IBBQ","LU2023250504.SGD","BK4139","IBB","BK4588","LU0823434583.USD","LU0823434740.USD","TBXU","LU0320765992.SGD","BK4585","LU0889565916.HKD","LU0114720955.EUR","LU2362541513.USD","LU0058720904.USD","LU2362541273.HKD","LU0882574055.USD","LU1974910355.USD","REGN","LU0823416689.USD","LU2237438978.USD","LU2089984988.USD","LU0289739699.SGD","LU2362540622.SGD","LU2468319806.SGD","LU2106854487.HKD","LU1917777945.USD","LU2324357040.USD","LU0053666078.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672765334","title":"Regeneron Pharmaceuticals, - 9-Month Median Duration of Response Observed at 800 Mg Ubamatamab Dose","url":"https://stock-news.laohu8.com/highlight/detail?id=2672765334","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672765334?lang=en_us&edition=fundamental","pubTime":"2026-10-01 23:35","pubTimestamp":1790868900,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nTUA9RS104:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0109394709.USD","BBH","IBBQ","LU2023250504.SGD","BK4139","IBB","BK4588","LU0823434583.USD","LU0823434740.USD","TBXU","LU0320765992.SGD","BK4585","LU0889565916.HKD","LU0114720955.EUR","LU2362541513.USD","LU0058720904.USD","LU2362541273.HKD","LU0882574055.USD","LU1974910355.USD","REGN","LU0823416689.USD","LU2237438978.USD","LU2089984988.USD","LU0289739699.SGD","LU2362540622.SGD","LU2468319806.SGD","LU2106854487.HKD","LU1917777945.USD","LU2324357040.USD","LU0053666078.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672653377","title":"Regeneron Pharmaceuticals, - Ubamatamab Shows 73% Objective Response Rate and 11-Month Median Pfs in Lgsoc Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2672653377","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672653377?lang=en_us&edition=fundamental","pubTime":"2026-10-01 23:35","pubTimestamp":1790868900,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nTUA9RS104:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","REGN","LU2362541513.USD","BK4139","LU2023250504.SGD","TBXU","LU2362540622.SGD","LU2089984988.USD","LU0889565916.HKD","LU0320765992.SGD","LU2362541273.HKD","LU0289739699.SGD","LU2106854487.HKD","LU1974910355.USD","IBB","LU1917777945.USD","LU0109394709.USD","BBH","LU2237438978.USD","LU0114720955.EUR","BK4588","LU2468319806.SGD","LU0823434740.USD","LU0882574055.USD","LU2324357040.USD","LU0058720904.USD","LU0823416689.USD","LU0053666078.USD","IBBQ","LU0823434583.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672653197","title":"Regeneron Pharmaceuticals, - Serious Teaes Grade 3+ in 21% of Lgsoc Patients; Traes in 74%; Neutropenia, Anemia, Elevated Liver Enzymes","url":"https://stock-news.laohu8.com/highlight/detail?id=2672653197","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672653197?lang=en_us&edition=fundamental","pubTime":"2026-10-01 23:35","pubTimestamp":1790868900,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nTUA9RS104:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0823434583.USD","LU2468319806.SGD","LU2362541513.USD","IBBQ","BK4585","LU2362540622.SGD","BK4588","LU1974910355.USD","BK4139","LU2089984988.USD","TBXU","LU0823434740.USD","REGN","LU0320765992.SGD","LU0058720904.USD","LU0889565916.HKD","BBH","IBB","LU2362541273.HKD","LU0882574055.USD","LU2237438978.USD","LU0289739699.SGD","LU2324357040.USD","LU0823416689.USD","LU2106854487.HKD","LU0053666078.USD","LU2023250504.SGD","LU0109394709.USD","LU1917777945.USD","LU0114720955.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672314765","title":"Regeneron Pharmaceuticals, - to Advance Ubamatamab into Confirmatory Phase 3 Trial for Lgsoc","url":"https://stock-news.laohu8.com/highlight/detail?id=2672314765","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672314765?lang=en_us&edition=fundamental","pubTime":"2026-10-01 23:35","pubTimestamp":1790868900,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nTUA9RS104:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LU0114720955.EUR","LU2468319806.SGD","REGN","LU2089984988.USD","LU2362540622.SGD","BK4585","LU0882574055.USD","IBBQ","LU1917777945.USD","LU2106854487.HKD","LU0289739699.SGD","LU0058720904.USD","LU0053666078.USD","LU0889565916.HKD","BK4588","LU0320765992.SGD","LU2023250504.SGD","IBB","LU0823416689.USD","LU2362541513.USD","LU2324357040.USD","LU0823434583.USD","LU0109394709.USD","LU1974910355.USD","LU2237438978.USD","LU2362541273.HKD","TBXU","BBH","LU0823434740.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672176533","title":"Ubamatamab (Muc16xcd3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (Lgsoc)","url":"https://stock-news.laohu8.com/highlight/detail?id=2672176533","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672176533?lang=en_us&edition=fundamental","pubTime":"2026-10-01 23:35","pubTimestamp":1790868900,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nTUA9RS104:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1974910355.USD","LU2324357040.USD","BK4588","BK4139","LU2362541513.USD","LU0882574055.USD","LU0109394709.USD","LU0823416689.USD","BK4585","LU2089984988.USD","TBXU","LU0823434583.USD","LU0320765992.SGD","LU0889565916.HKD","LU2362541273.HKD","IBB","LU2468319806.SGD","BBH","LU0053666078.USD","LU0823434740.USD","LU0289739699.SGD","LU2023250504.SGD","LU1917777945.USD","LU2362540622.SGD","LU2237438978.USD","LU0058720904.USD","LU2106854487.HKD","IBBQ","LU0114720955.EUR","REGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672765309","title":"Ubamatamab (MUC16xCD3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (LGSOC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2672765309","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672765309?lang=en_us&edition=fundamental","pubTime":"2026-10-01 23:35","pubTimestamp":1790868900,"startTime":"0","endTime":"0","summary":"LGSOC is a biologically distinct variant of ovarian cancer, with limited treatment options, that is generally less responsive to conventional chemotherapy Results presented in a late-breaking plenary ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/01/3373161/0/en/ubamatamab-muc16xcd3-shows-a-high-rate-of-durable-responses-in-initial-study-of-patients-with-advanced-low-grade-serous-ovarian-cancer-lgsoc.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2324357040.USD","NOBL","LU0058720904.USD","BBH","LU1974910355.USD","LU2362541273.HKD","IE00B19Z4B17.USD","BK4588","LU2931357623.SGD","LU0114720955.EUR","LU0274383776.USD","LU0823434583.USD","LU2023250504.SGD","IXJ","LU0823434740.USD","REGN","IE00B66KJ199.SGD","LU0823416689.USD","LU0757428866.USD","LU2468319806.SGD","VHT","BK4104","LU0109394709.USD","LU0882574055.USD","LU1917777945.USD","BCC","IBB","BK4567","LU2237438978.USD","BK4585","TCAF","TBXU","LU0053666078.USD","LU2089985449.USD","IBBQ","LU1815336091.USD","LU2089984988.USD","BK4550","BK4157","LU0889565916.HKD","IE00B7SZL793.SGD","AEIS","LU2362541513.USD","CGCV","BK4139","LU0320765992.SGD","LU2106854487.HKD","LU2362540622.SGD","IE0031619046.USD","LU0289739699.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672813765","title":"Regeneron Says Phase 2 Courage Trial Shows Trevogrumab Preserves Lean Mass During Semaglutide Weight Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2672813765","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672813765?lang=en_us&edition=fundamental","pubTime":"2026-10-01 23:31","pubTimestamp":1790868665,"startTime":"0","endTime":"0","summary":"Regeneron says Phase 2 COURAGE trial shows trevogrumab preserves lean mass during semaglutide weight lossRegeneron reported new Phase 2 COURAGE results showing trevogrumab helped preserve muscle durin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nNDL2GbBGj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1917777945.USD","LU0889565916.HKD","LU2095319765.USD","LU2362541273.HKD","BK4139","IE00BN0W2W23.USD","SG9999014013.SGD","LU2237438978.USD","LU2362540622.SGD","LU0823416689.USD","LU2324357040.USD","IE00BQXX3D17.EUR","LU2468319806.SGD","IE00BQXX3F31.USD","LU2362541513.USD","IE00BN0W2T93.GBP","LU0289739699.SGD","NDAQ","LU0882574055.USD","IE00BN0W2V16.EUR","LU2106854487.HKD","SG9999014021.USD","LU2023250504.SGD","BCDF","LU0058720904.USD","IE00BQXX3C00.GBP","LU2210150020.SGD","BK4588","LU1974910355.USD","LU0823434740.USD","LU2210149790.SGD","LU0320765992.SGD","LU2089984988.USD","BBH","LU0314104364.USD","BK4112","IE00B64PRP62.GBP","LU0114720955.EUR","IBBQ","LU0053666078.USD","IE00BGHQF748.EUR","LU0823434583.USD","SG9999014039.USD","LU0109394709.USD","IBB","BK4585","TBXU","REGN","SG9999014005.SGD","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672888765","title":"Regeneron Pharmaceuticals, - Lower Doses of Trevogrumab Well Tolerated with 77% Experiencing at Least One Adverse Event","url":"https://stock-news.laohu8.com/highlight/detail?id=2672888765","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672888765?lang=en_us&edition=fundamental","pubTime":"2026-10-01 23:30","pubTimestamp":1790868600,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nTUA5R1YTR:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2324357040.USD","LU0823434740.USD","LU1917777945.USD","LU2237438978.USD","LU2362541513.USD","LU2106854487.HKD","LU2089984988.USD","BK4585","BK4588","LU2362541273.HKD","LU0889565916.HKD","REGN","BBH","LU0109394709.USD","LU1974910355.USD","LU0053666078.USD","LU0823434583.USD","IBBQ","LU0114720955.EUR","LU2468319806.SGD","IBB","LU2023250504.SGD","LU2362540622.SGD","BK4139","LU0289739699.SGD","LU0320765992.SGD","LU0823416689.USD","LU0882574055.USD","LU0058720904.USD","TBXU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672884765","title":"Regeneron Pharmaceuticals, - Plans Phase 2 Trial of Trevogrumab with Glp-1 Therapies in Older Adults","url":"https://stock-news.laohu8.com/highlight/detail?id=2672884765","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672884765?lang=en_us&edition=fundamental","pubTime":"2026-10-01 23:30","pubTimestamp":1790868600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nTUA5R1YTR:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1974910355.USD","LU0053666078.USD","LU2237438978.USD","LU0114720955.EUR","LU0058720904.USD","REGN","LU0882574055.USD","BK4139","LU2468319806.SGD","LU0823416689.USD","LU2106854487.HKD","LU2324357040.USD","LU2362541273.HKD","BBH","IBBQ","LU0320765992.SGD","LU2362541513.USD","LU2023250504.SGD","LU0109394709.USD","LU0889565916.HKD","BK4585","LU0289739699.SGD","LU1917777945.USD","BK4588","LU0823434740.USD","LU2362540622.SGD","LU0823434583.USD","LU2089984988.USD","IBB","TBXU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672765886","title":"Phase 2 Courage Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During Glp-1 Receptor Agonist-Induced Weight Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2672765886","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672765886?lang=en_us&edition=fundamental","pubTime":"2026-10-01 23:30","pubTimestamp":1790868600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nTUA5R1YTR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TBXU","LU2468319806.SGD","LU2023250504.SGD","LU2324357040.USD","REGN","LU0053666078.USD","LU0889565916.HKD","LU0114720955.EUR","LU1917777945.USD","LU1974910355.USD","BK4588","LU2362541513.USD","IBBQ","LU2237438978.USD","LU0823434583.USD","LU2362540622.SGD","LU0320765992.SGD","LU0058720904.USD","BK4139","LU2362541273.HKD","LU0109394709.USD","BBH","LU0882574055.USD","LU0823416689.USD","LU0823434740.USD","LU2106854487.HKD","LU0289739699.SGD","BK4585","IBB","LU2089984988.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672763000","title":"Regeneron Pharmaceuticals, - Trevogrumab Prevents 70% of Muscle Loss Associated with Semaglutide Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2672763000","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672763000?lang=en_us&edition=fundamental","pubTime":"2026-10-01 23:30","pubTimestamp":1790868600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nTUA5R1YTR:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2237438978.USD","BK4139","LU0289739699.SGD","LU0109394709.USD","BBH","LU1974910355.USD","LU1917777945.USD","LU0823434740.USD","LU2106854487.HKD","IBBQ","LU2089984988.USD","LU0823434583.USD","LU0889565916.HKD","REGN","LU0114720955.EUR","LU2324357040.USD","LU2362541513.USD","BK4588","LU2468319806.SGD","LU0882574055.USD","TBXU","LU0320765992.SGD","IBB","LU2023250504.SGD","LU2362541273.HKD","BK4585","LU0823416689.USD","LU2362540622.SGD","LU0053666078.USD","LU0058720904.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672500697","title":"Gilead Sciences Announces Dividend of R$ 0.2394442440 Per Unit for Brgildbdr 000","url":"https://stock-news.laohu8.com/highlight/detail?id=2672500697","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672500697?lang=en_us&edition=fundamental","pubTime":"2026-10-01 21:56","pubTimestamp":1790863001,"startTime":"0","endTime":"0","summary":"Gilead Sciences announces dividend of R$ 0.2394442440 per unit for BRGILDBDR 000Gilead declared a 3Q 2026 dividend of R$ 0.2394 per unit for ISIN BRGILDBDR000.Shares trade ex-rights from Sept. 11, 202","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nNDL7w2sZC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1778281490.HKD","SG9999015978.USD","BK4550","IE00B19Z3B42.SGD","LU0859254822.USD","LU1066053197.SGD","IBBQ","LU0861579265.USD","BK4585","LU0122379950.USD","LU0965509101.SGD","LU1934455277.USD","LU1934455863.HKD","BK4588","BK4139","LU2089984988.USD","LU1057294990.SGD","SG9999015945.SGD","TBXU","BIB","LU1037948541.HKD","LU0320765992.SGD","LU0965508806.USD","LU1066051498.USD","MEDI","LU0058720904.USD","LU2357627491.SGD","BK4568","BBH","LU0889565916.HKD","IE00B19Z3581.USD","IBB","LU1023059063.AUD","LU1430594728.SGD","LU1037948897.HKD","GILD","TMED","LU1571399168.USD","IE00B7SZLL34.SGD","LU1061106388.HKD","LU0965509010.AUD","LU0823416689.USD","SG9999015986.USD","LU0965509283.SGD","IE00B3T34201.USD","IE00BZ1G4Q59.USD","BMED","LU0109394709.USD","IE0002270589.USD","LU0114720955.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672757352","title":"Regeneron Exec Says Co Eligible to Receive $1 Bln in Potential Milestone Payment with the Start of the First Late-Stage Trial as Part of the Deal -Conf Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2672757352","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672757352?lang=en_us&edition=fundamental","pubTime":"2026-10-01 20:47","pubTimestamp":1790858840,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nFWN45N1JO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0823434740.USD","IBBQ","REGN","LU0882574055.USD","BK4585","LU0058720904.USD","LU1917777945.USD","LU2362541273.HKD","LU0053666078.USD","LU0823416689.USD","LU1974910355.USD","BBH","TBXU","BK4588","LU0889565916.HKD","LU0320765992.SGD","LU2106854487.HKD","LU2362540622.SGD","LU0109394709.USD","LU0114720955.EUR","LU2362541513.USD","LU2237438978.USD","LU0289739699.SGD","LU0823434583.USD","LU2023250504.SGD","LU2089984988.USD","LU2468319806.SGD","LU2324357040.USD","IBB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672514757","title":"Regeneron Exec Says Co Expects to Start Pivotal Study for Regn20423 Either in Late 2027 or Early 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2672514757","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672514757?lang=en_us&edition=fundamental","pubTime":"2026-10-01 20:47","pubTimestamp":1790858840,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nFWN45N1JO:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["REGN","LU0114720955.EUR","LU0823434740.USD","LU2362540622.SGD","LU0889565916.HKD","LU2362541273.HKD","BBH","BK4139","LU0320765992.SGD","LU0053666078.USD","LU0058720904.USD","LU0882574055.USD","LU1974910355.USD","LU2089984988.USD","LU2106854487.HKD","LU2324357040.USD","TBXU","IBB","LU2362541513.USD","IBBQ","LU0823416689.USD","BK4588","LU1917777945.USD","BK4585","LU2023250504.SGD","LU0289739699.SGD","LU0109394709.USD","LU0823434583.USD","LU2237438978.USD","LU2468319806.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672573987","title":"Regeneron Pharma Price Target Announced at $850.00/Share by Argus Research","url":"https://stock-news.laohu8.com/highlight/detail?id=2672573987","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672573987?lang=en_us&edition=fundamental","pubTime":"2026-10-01 20:46","pubTimestamp":1790858760,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/REGN/analyst-ratings","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Regeneron Pharma Price Target Announced at $850.00/Share by Argus Research","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0114720955.EUR","LU0058720904.USD","LU0823434583.USD","BBH","LU0109394709.USD","REGN","LU2362540622.SGD","LU2023250504.SGD","LU1974910355.USD","LU0823434740.USD","LU0823416689.USD","LU0889565916.HKD","LU2237438978.USD","LU2324357040.USD","LU2362541513.USD","LU2362541273.HKD","BK4588","IBB","BK4585","LU2106854487.HKD","BK4139","TBXU","IBBQ","LU0289739699.SGD","LU1917777945.USD","LU0053666078.USD","LU2468319806.SGD","LU0882574055.USD","LU0320765992.SGD","LU2089984988.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672752471","title":"Vir Biotechnology Names Aziz Sawaf as CFO Effective Oct. 5, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2672752471","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672752471?lang=en_us&edition=fundamental","pubTime":"2026-10-01 20:31","pubTimestamp":1790857866,"startTime":"0","endTime":"0","summary":"Vir Biotechnology names Aziz Sawaf as CFO effective Oct. 5, 2026Vir Biotechnology appointed Aziz Sawaf as executive vice president and chief financial officer, effective Oct. 5, 2026.Sawaf will overse","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nNDL7MZVyh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2324357040.USD","IBBQ","TBXU","LU0889565916.HKD","BK4532","LU0320765992.SGD","LU1037948897.HKD","BBH","LU0965508806.USD","LU1674673428.USD","LU1037948541.HKD","BMED","BK4583","SG9999015945.SGD","BK4566","LU0234570918.USD","LU1066051498.USD","LU1778281490.HKD","VIR","IE00B7SZLL34.SGD","IE00BZ1G4Q59.USD","LU0058720904.USD","LU2357627491.SGD","IBB","BK4585","LU2089984988.USD","LU2468319806.SGD","ZYME","GILD","LU1430594728.SGD","LU2087621335.USD","BIB","LU0965509101.SGD","SG9999015952.SGD","BK4588","LU1066053197.SGD","LU0965509283.SGD","MEDI","LU1674673691.USD","LU1571399168.USD","BK4139","BK4578","IE0002270589.USD","LU0859254822.USD","TMED","LU0861579265.USD","LU1061106388.HKD","LU0965509010.AUD","IE00B19Z3B42.SGD","IE00B3T34201.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":5,"totalSize":200,"code":"91000000","status":"200"}]}}